This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
by Zacks Equity Research
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
by Zacks Equity Research
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.
Esperion (ESPR) Reports Positive Data From CLEAR Study
by Zacks Equity Research
Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.
Why Is Esperion Therapeutics (ESPR) Down 16.7% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
by Zacks Equity Research
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
by Zacks Equity Research
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
by Zacks Equity Research
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
by Zacks Equity Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Wall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has UnitedHealth Group (UNH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how UnitedHealth Group (UNH) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is United Therapeutics (UTHR) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.